No connection

Search Results

DVA vs JNJ

DVA
DaVita Inc.
NEUTRAL
Price
$151.85
Market Cap
$10.01B
Sector
Healthcare
AI Confidence
85%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
DVA
15.97
JNJ
21.55
Forward P/E
DVA
9.26
JNJ
18.9
P/B Ratio
DVA
-15.99
JNJ
7.03
P/S Ratio
DVA
0.73
JNJ
6.09
EV/EBITDA
DVA
8.77
JNJ
17.81

Profitability

Gross Margin
DVA
32.26%
JNJ
68.08%
Operating Margin
DVA
15.23%
JNJ
23.97%
Profit Margin
DVA
5.47%
JNJ
28.46%
ROE
DVA
64.85%
JNJ
35.03%
ROA
DVA
7.32%
JNJ
8.68%

Growth

Revenue Growth
DVA
9.9%
JNJ
9.1%
Earnings Growth
DVA
6.5%
JNJ
48.6%

Financial Health

Debt/Equity
DVA
11.11
JNJ
0.6
Current Ratio
DVA
1.29
JNJ
1.03
Quick Ratio
DVA
1.17
JNJ
0.69

Dividends

Dividend Yield
DVA
--
JNJ
2.19%
Payout Ratio
DVA
0.0%
JNJ
46.6%

AI Verdict

DVA NEUTRAL

DaVita Inc. presents a dichotomy between attractive valuation and precarious financial leverage, anchored by a stable but mediocre Piotroski F-Score of 4/9. While the stock trades at a compelling Forward P/E of 9.26 and a PEG ratio of 0.56, suggesting significant undervaluation relative to growth, this is offset by an extreme Debt/Equity ratio of 11.11 and negative book value. Bearish insider sentiment, characterized by a $199.94M sale, and a weak technical trend (10/100) further temper the bullish case. The stock is currently trading very close to its analyst target price and intrinsic value, leaving limited immediate upside.

Strengths
Highly attractive valuation with a Forward P/E of 9.26
Strong growth efficiency indicated by a PEG ratio of 0.56
Consistent historical track record of earnings beats over 25 quarters
Risks
Extreme financial leverage with a Debt/Equity ratio of 11.11
Negative Price/Book ratio (-15.99) indicating negative shareholder equity
Strongly bearish insider activity with significant recent selling
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

DVA vs JNJ: Head-to-Head Comparison

This page compares DaVita Inc. (DVA) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile